NT-077 is a repurposed medicine that we are currently developing as a potential best-in-class, self-administered, once-daily, topical therapy for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating.

Just recently, a first-in-human phase I clinical study was completed. The study was conducted in two parts; in part I, subjects were treated in an open-label design with three different dose levels of NT-077, applied to one or both axillae; in part II the same subjects were treated in randomized, double-blind, placebo-controlled design with one selected dose of NT-077 for seven days applied to one axilla, versus vehicle (placebo) applied to the contralateral axilla. The study was conducted in compliance with current EU GCP regulations by a CRO in the Netherlands. Soon we hope to announce topline results from this first-in-human phase I clinical study for NT-077 spray solution.